TIDMHEMO
RNS Number : 0151P
Hemogenyx Pharmaceuticals PLC
04 June 2020
Hemogenyx Pharmaceuticals plc
(the "Company")
Result of Annual General Meeting and Completion of Placing
Hemogenyx Pharmaceuticals plc is pleased to announce that, at
the Annual General Meeting ("AGM") held earlier today, all
resolutions were duly passed. The numbers of votes for each
resolution are presented at the end of this announcement.
Completion of Placing
Following the shareholders' vote at the AGM to authorise the
Directors to allot shares for cash, the Conditional Placing
announced on 12 May 2020 to raise GBP2,500,000 (before expenses) at
7p per share has now become unconditional. Accordingly, 35,714,286
new ordinary shares of 1p each (the "Placing Shares") will now be
allotted. An application has been made for the Placing Shares to be
admitted to the Official List of the UK Listing Authority by way of
a Standard Listing ("Admission") and it is expected that Admission
will become effective and that dealing in the Placing Shares will
commence on or around 5 June 2020. The Placing Shares will rank
pari passu with the existing ordinary shares of the Company.
Operational Update
As it has not been possible to open up the AGM to shareholder
discussion in the normal way a brief update on operations and
developments is provided below.
As announced on 2 June 2020, the Company has agreed a
three-month extension of the collaboration with a leading global
pharmaceutical company ( " GlobalCo " ) for the successful
preclinical development of the Company's lead candidate bi-specific
CDX antibody. This collaboration complements the Company's own
development work that is currently being undertaken. The Directors
are pleased to have agreed this extension which shows GlobalCo's
continuing commitment to the project despite delays created by the
COVID-19 pandemic crisis which has seen the industry as a whole
focussing on treatments for COVID-19 while being hampered by
laboratory shutdowns over recent months.
The fundraising will also enable the Company to progress its own
work on COVID-19 and other viruses considerably more intensively.
The Company had already been developing treatments to be deployed
against other viral pathogens prior to the onset of COVID-19. The
Company's ApbHC mice have been developed in part as a discovery
platform for the development of such treatments. The Directors
believe, for example, that the ApbHC could potentially be used as a
tool for the rapid discovery and/or isolation of human antibodies
against previously unknown viruses such as the novel coronavirus or
other natural or engineered human-specific pathogens, referred to
in biodefence circles as "Disease X".
The funds raised will also be used to advance IND-enabling
studies for HEMO-CAR-T, the Company's product candidate which is
being developed for the treatment of blood cancers such as AML
(acute myeloid leukaemia), particularly with the aim of creating a
"tuneable and controllable drug" which would greatly enhance the
safety and versatility of HEMO-CAR-T cells in relation to blood
cancers in an area where CAR-T based treatment has had some success
but where current efficacy and safety is far from perfect.
The Directors believe that a number of developments, in
particular those mentioned above, have shown excellent results to
date and look forward to taking these forward effectively in the
coming months.
Total Voting Rights
Following Admission, the issued share capital of the Company
will comprise 433,636,255 ordinary shares of 1p each. No ordinary
shares are held in Treasury. The total number of voting rights in
the Company will therefore be 433,636,255 and this figure may be
used by shareholders of the Company as the denominator for the
calculations by which they will determine if they are required to
notify their investment in, or a change in their interest in, the
share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
AGM Voting Results
Ordinary Resolutions Votes for % of Votes % of Total votes Total Votes
votes Against votes cast votes withheld
cast cast cast (2)
for against as %
of ISC
(1)
1. To approve
the Company's
annual accounts
for the financial
year ended 31
December 2019 143,613,948 100% 0 0% 143,613,948 36.1% 3,494
------------ ------- --------- --------- ------------ -------- ----------
2. To approve
the directors'
remuneration report
contained within
the annual report
and accounts for
the financial
year ended 31
December 2019 143,610,005 100% 0 0% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
3. To re-elect
Dr Vladislav Sandler
as a director
of the Company 143,613,499 100% 0 0% 143,613,499 36.1% 3,943
------------ ------- --------- --------- ------------ -------- ----------
4. To re-elect
Alexis Sandler
as a director
of the Company 143,610,005 100% 0 0% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
5. To re-elect
Peter Redmond
as a director
of the Company 143,610,005 100% 0 0% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
6. To re-appoint
PKF Littlejohn
LLP as auditor
of the Company 143,610,005 100% 0 0% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
7. To authorise
the directors
to determine the
level of the auditor's
remuneration 143,610,005 100% 0 0% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
8. To provide
the directors
with authority
to allot ordinary
shares 143,585,991 99.98% 24,014 0.02% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
Special Resolutions Votes for % of Votes % of Total votes Total Votes
votes against votes cast votes withheld
cast cast cast (2)
for against as %
of ISC
(1)
------------ ------- --------- --------- ------------ -------- ----------
9. To disapply
statutory pre-emption
rights 143,405,991 99.86% 204,014 0.14% 143,610,005 36.1% 7,437
------------ ------- --------- --------- ------------ -------- ----------
(1) The Company's issued share capital (" ISC") on 2 June 2020,
being the date on which members had to be entered in the register
of members of the Company in order to be entitled to attend and
vote at the meeting, was 397,921,969 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote
in law and is not counted in the calculation of the proportion of
the votes for and against it.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEALKLEFAEEFA
(END) Dow Jones Newswires
June 04, 2020 10:15 ET (14:15 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024
